Our focus:
Understanding how and why an otherwise ‘tumor-restrictive’ stroma evolves into a ‘tumor-permissive’ stroma. We believe that therapies restoring the tumor restrictive stroma by normalizing ECM turnover are the future of clinical cancer research.  

Our relevance:
The hallmark of a ‘tumor-permissive’ stroma is a disruption of tissue microarchitecture and altered extracellular matrix (ECM) remodeling. The ECM alterations in the tumor fuels a vicious cycle of stromal dissemination enriching for cancer-associated fibroblast (CAFs), desmoplasia, immunosuppression and epithelial-to-mesenchymal transition leading to poor efficacy of interventions.


Our current approach:
A patient-centric approach to evaluate ECM biomarkers in clinical trials with the potential to predict the likelihood of response and elaborate on MoA by monitoring direct or ‘bystander’ effect on the ECM. In contrast to most other liquid biopsies that focus on circulating tumor DNA (ctDNA) or circulating tumor cells (CSCs), at Nordic Bioscience we focus our biomarker efforts on targeting and quantifying post-translational modifications (PTMs) on proteins or peptide fragments in circulation.


The Protein Fingerprint Technology allows for a tumor agnostic approach (solid tumors) to address tumor microenvironment alterations that can be tracked to specific cellular and biological processes through non-invasive quantification of ECM turnover and with clear value for drug development and benefit for patients.

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.

We use cookies on our site to enable essential services and functionalities, and collect data in regards to visitor information. This is done in order to provide the best possible experience for the visitor. Cookie policy Privacy statement